



GP1625
#6
Admon
6/10/00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Barta et al.)
Serial No.: 09/311,837) Attorney Docket
Filed: May 14, 1999) 6221/75962
For: AROMATIC SULFONE HYDROXAMIC) MON-116.6
ACID METALLOPROTEASE INHIBITOR)
Examiner: C. Chang) Art Group:
1625

ELECTION

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Election requirement mailed May 8, 2000, Claim Group II is hereby elected without traverse.


Claim Group II includes claims 93 and 94, as well as generic compound claims 52-85 and 87-92. The Restriction noted that composition claims 128-131 and method claims 7-33 and 35-40 would also be considered "upon election of a single pathology to be treatable..." The treatable pathology is angiogenesis whose treatment is discussed in Example 447 at page 880. Process of making claims 41 and 42 were also said to be prosecutable to the extent of making the election.

It is believed that this application is in condition for an action on the merits and for allowance of all of the claims. An early notice to that effect is earnestly solicited.

No further fee or petition is believed to be necessary. However, should any further fee be needed, please charge our Deposit Account No. 23-0920, and deem this paper to be the required petition.

The Examiner is requested to phone the undersigned should any questions arise that can be dealt with over the phone to expedite this prosecution.

Respectfully submitted,

By 
Edward P. Gamson, Reg. No. 29,381

WELSH & KATZ, LTD.
120 South Riverside Plaza, 22nd Floor
Chicago, Illinois 60606
Phone (312) 655-1500
Fax No. (312) 655-1501